IL17A and myeloid sarcoma: With respect to IL17, there was a slight and nonsignificant (p = 0.4) increase in MS patients by 1.9 (0–15) and 1.2 (0–15), respectively (Figure 3B), while no significant (p = 0.8) difference was found in IL6 (0–18) compared with the control group (0–39) pg/mL, (Figure 3C).